Anlotinib Hydrochloride: Precision VEGFR2/PDGFRβ/FGFR1 Inhibitor for Anti-Angiogenic Cancer Research

Executive Summary: Anlotinib hydrochloride is a novel small-molecule tyrosine kinase inhibitor (TKI) that targets VEGFR2, PDGFRβ, and FGFR1 with nanomolar potency, providing high specificity for anti-angiogenic research (Lin et al., 2018). It robustly inhibits VEGF/PDGF-BB/FGF-2-induced endothelial cell migration and tube formation in vitro. Pharmacokinetic studies show high oral bioavailability and wide tissue distribution, including tumor and brain. Comparative benchmarks reveal superior efficacy over sunitinib, sorafenib, and nintedanib. APExBIO offers rigorously characterized anlotinib (hydrochloride) (SKU C8688) for advanced experimental workflows (product page).

Biological Rationale

Angiogenesis is essential for tumor growth and metastasis, enabling tumors to acquire nutrients and oxygen by forming new blood vessels (Lin et al., 2018). Three major signaling axes—VEGF/VEGFR2, PDGF/PDGFRβ, and FGF-2/FGFR1—drive endothelial cell proliferation, migration, and capillary tube formation. VEGFA is highly expressed in most cancers and binds VEGFR2 to trigger downstream ERK pathway activation. FGF-2 and PDGF-BB similarly activate FGFR1 and PDGFRβ, respectively. Inhibiting these pathways blocks neovascularization and can limit tumor progression. Multi-target TKIs, such as anlotinib, have emerged as key tools for dissecting angiogenic mechanisms in cancer biology (APExBIO internal).

Mechanism of Action of Anlotinib (hydrochloride)

Anlotinib (hydrochloride) acts as a multi-target TKI, primarily inhibiting VEGFR2 (IC₅₀: 5.6 ± 1.2 nM), PDGFRβ (IC₅₀: 8.7 ± 3.4 nM), and FGFR1 (IC₅₀: 11.7 ± 4.1 nM) (Lin et al., 2018). This inhibition is concentration-dependent and blocks the phosphorylation of these receptors, preventing activation of downstream pathways such as ERK. As a result, anlotinib disrupts endothelial cell migration and formation of capillary-like structures, key processes in angiogenesis. Compared to clinically used TKIs like sunitinib, sorafenib, and nintedanib, anlotinib exhibits improved selectivity and efficacy against these targets (internal contrast: details comparative cell-based benchmarks).

Evidence & Benchmarks

• Anlotinib inhibits VEGF/PDGF-BB/FGF-2-induced migration of EA.hy 926 endothelial cells in vitro, with statistically significant reductions compared to control (Lin et al. 2018, DOI).
• Capillary tube formation assays demonstrate dose-dependent disruption of angiogenesis, with anlotinib outperforming sunitinib, sorafenib, and nintedanib on matched endpoints (Lin et al. 2018, DOI).
• Pharmacokinetic studies in rats and dogs report oral bioavailability of 28–58% and 41–77% respectively; human plasma protein binding is 93% (APExBIO, product).
• Tissue distribution studies reveal accumulation in tumor, lung, liver, kidney, heart, and ability to cross the blood-brain barrier (APExBIO, source).
• Acute toxicity (14-day oral LD₅₀) is 1735.9 mg/kg; no significant organ or genetic toxicity in preclinical models (APExBIO, source).
• In vivo angiogenesis inhibition validated in rat aortic ring and chicken CAM assays (Lin et al. 2018, DOI).
• Mechanistic studies confirm ERK pathway phosphorylation is suppressed downstream of receptor inhibition (Lin et al. 2018, DOI).

This article extends earlier overviews such as "Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor" by providing comparative human and animal pharmacokinetic data and clarifying tissue distribution parameters.

Applications, Limits & Misconceptions

Anlotinib hydrochloride is used in research settings for:

• Cellular angiogenesis assays (e.g., endothelial cell migration, tube formation).
• Dissecting signaling via VEGFR2/PDGFRβ/FGFR1 and ERK pathways.
• Tumor and vascular tissue modeling in preclinical animal studies (Lin et al., 2018).

It is not approved for diagnostic or therapeutic use in humans. All in vitro and in vivo data should be interpreted within the context of controlled research protocols (APExBIO).

Common Pitfalls or Misconceptions

• Not a clinical drug product: Anlotinib (hydrochloride) C8688 from APExBIO is for research use only; it is not suitable for human therapy.
• Selective but not universal: While highly potent against VEGFR2/PDGFRβ/FGFR1, it may not inhibit unrelated kinases or angiogenic factors outside these pathways.
• Assay dependency: Results may vary between cell line models and species; dosing and endpoint definition are critical (see assay troubleshooting).
• Storage conditions: Compound stability requires -20°C storage; improper handling can affect activity.
• Not for genetic studies: Does not directly edit or modulate gene expression; acts only via kinase inhibition.

For guidance on workflow optimization and reproducibility, see "Optimizing Tumor Angiogenesis Assays with Anlotinib (hydrochloride)", which this article updates with new pharmacokinetic and safety insights.

Workflow Integration & Parameters

Anlotinib (hydrochloride) is typically dissolved in DMSO for in vitro studies, with working concentrations ranging from 1–100 nM depending on assay sensitivity. For cell migration and tube formation assays, human EA.hy 926 endothelial cells are recommended as the model system. Endpoint readouts include quantitative migration (scratch/wound healing, Boyden chamber) and capillary tube formation metrics. For in vivo work, dosing protocols should reflect validated preclinical animal models, with careful control of route and formulation (Lin et al., 2018).

The C8688 kit from APExBIO provides batch-validated anlotinib hydrochloride for reproducible research. Storage at -20°C is mandatory. For advanced troubleshooting and experimental design support, refer to "Solving Lab Challenges with Anlotinib (hydrochloride)", which focuses on real-world assay optimization beyond the mechanistic focus of this article.

Conclusion & Outlook

Anlotinib (hydrochloride) is a best-in-class tool for dissecting tumor angiogenesis, with nanomolar potency against VEGFR2, PDGFRβ, and FGFR1, and excellent pharmacokinetic and safety profiles in preclinical models. It enables precise perturbation of angiogenic signaling in cancer research and provides an experimentally validated alternative to legacy TKIs. As more mechanistic and translational data accumulate, anlotinib will continue to anchor advanced anti-angiogenic assay workflows. For full product specifications and ordering, see APExBIO’s Anlotinib (hydrochloride) reference page.